Literature DB >> 35224705

SARM1 can be a potential therapeutic target for spinal cord injury.

Qicheng Lu1, Benson O A Botchway2, Yong Zhang1, Tian Jin1, Xuehong Liu3.   

Abstract

Injury to the spinal cord is devastating. Studies have implicated Wallerian degeneration as the main cause of axonal destruction in the wake of spinal cord injury. Therefore, the suppression of Wallerian degeneration could be beneficial for spinal cord injury treatment. Sterile alpha and armadillo motif-containing protein 1 (SARM1) is a key modulator of Wallerian degeneration, and its impediment can improve spinal cord injury to a significant degree. In this report, we analyze the various signaling domains of SARM1, the recent findings on Wallerian degeneration and its relation to axonal insults, as well as its connection to SARM1, the mitogen-activated protein kinase (MAPK) signaling, and the survival factor, nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2). We then elaborate on the possible role of SARM1 in spinal cord injury and explicate how its obstruction could potentially alleviate the injury.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Axonal degeneration; Mitogen-activated protein kinase (MAPK) signaling; Nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2); Spinal cord injury; Sterile alpha and armadillo motif-containing protein 1 (SARM1); Wallerian degeneration

Mesh:

Substances:

Year:  2022        PMID: 35224705     DOI: 10.1007/s00018-022-04195-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  97 in total

Review 1.  Wallerian degeneration, wld(s), and nmnat.

Authors:  Michael P Coleman; Marc R Freeman
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

2.  Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1.

Authors:  Nils Henninger; James Bouley; Elif M Sikoglu; Jiyan An; Constance M Moore; Jean A King; Robert Bowser; Marc R Freeman; Robert H Brown
Journal:  Brain       Date:  2016-02-11       Impact factor: 13.501

Review 3.  Acute spinal cord injury: A review of pathophysiology and potential of non-steroidal anti-inflammatory drugs for pharmacological intervention.

Authors:  Emrullah Hayta; Hasan Elden
Journal:  J Chem Neuroanat       Date:  2017-08-10       Impact factor: 3.052

Review 4.  Wallerian degeneration as a therapeutic target in traumatic brain injury.

Authors:  Vassilis E Koliatsos; Athanasios S Alexandris
Journal:  Curr Opin Neurol       Date:  2019-12       Impact factor: 5.710

Review 5.  Traumatic Spinal Cord Injury-Repair and Regeneration.

Authors:  Christopher S Ahuja; Satoshi Nori; Lindsay Tetreault; Jefferson Wilson; Brian Kwon; James Harrop; David Choi; Michael G Fehlings
Journal:  Neurosurgery       Date:  2017-03-01       Impact factor: 4.654

Review 6.  Curcumin Can Improve Spinal Cord Injury by Inhibiting TGF-β-SOX9 Signaling Pathway.

Authors:  Jiaying Yuan; Benson O A Botchway; Yong Zhang; Xiaoning Tan; Xizhi Wang; Xuehong Liu
Journal:  Cell Mol Neurobiol       Date:  2019-03-26       Impact factor: 5.046

7.  Pharmacological bypass of NAD+ salvage pathway protects neurons from chemotherapy-induced degeneration.

Authors:  Hui-Wen Liu; Chadwick B Smith; Mark S Schmidt; Xiaolu A Cambronne; Michael S Cohen; Marie E Migaud; Charles Brenner; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-26       Impact factor: 11.205

8.  Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures.

Authors:  Donald V Bradshaw; Andrew K Knutsen; Alexandru Korotcov; Genevieve M Sullivan; Kryslaine L Radomski; Bernard J Dardzinski; Xiaomei Zi; Dennis P McDaniel; Regina C Armstrong
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

Review 9.  Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms.

Authors:  Anam Anjum; Muhammad Da'in Yazid; Muhammad Fauzi Daud; Jalilah Idris; Angela Min Hwei Ng; Amaramalar Selvi Naicker; Ohnmar Htwe Rashidah Ismail; Ramesh Kumar Athi Kumar; Yogeswaran Lokanathan
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

10.  Gene therapy targeting SARM1 blocks pathological axon degeneration in mice.

Authors:  Stefanie Geisler; Shay X Huang; Amy Strickland; Ryan A Doan; Daniel W Summers; Xianrong Mao; Jiwoong Park; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  J Exp Med       Date:  2019-01-14       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.